These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 12368671)

  • 1. Posttransplant lymphoproliferative disorders in liver transplantation: a 20-year experience.
    Jain A; Nalesnik M; Reyes J; Pokharna R; Mazariegos G; Green M; Eghtesad B; Marsh W; Cacciarelli T; Fontes P; Abu-Elmagd K; Sindhi R; Demetris J; Fung J
    Ann Surg; 2002 Oct; 236(4):429-36; discussion 436-7. PubMed ID: 12368671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreasing incidence of symptomatic Epstein-Barr virus disease and posttransplant lymphoproliferative disorder in pediatric liver transplant recipients: report of the studies of pediatric liver transplantation experience.
    Narkewicz MR; Green M; Dunn S; Millis M; McDiarmid S; Mazariegos G; Anand R; Yin W;
    Liver Transpl; 2013 Jul; 19(7):730-40. PubMed ID: 23696264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single-center experience of post-transplant lymphoproliferative disorder (PTLD) cases after pediatric liver transplantation: Incidence, outcomes, and association with food allergy.
    Barış Z; Özçay F; Yılmaz Özbek Ö; Haberal N; Sarıalioğlu F; Haberal M
    Turk J Gastroenterol; 2018 May; 29(3):354-360. PubMed ID: 29755021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between liver transplantation for Langerhans cell histiocytosis, rejection, and development of posttransplant lymphoproliferative disease in children.
    Newell KA; Alonso EM; Kelly SM; Rubin CM; Thistlethwaite JR; Whitington PF
    J Pediatr; 1997 Jul; 131(1 Pt 1):98-104. PubMed ID: 9255199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus.
    Sokal EM; Antunes H; Beguin C; Bodeus M; Wallemacq P; de Ville de Goyet J; Reding R; Janssen M; Buts JP; Otte JB
    Transplantation; 1997 Nov; 64(10):1438-42. PubMed ID: 9392308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression.
    Newell KA; Alonso EM; Whitington PF; Bruce DS; Millis JM; Piper JB; Woodle ES; Kelly SM; Koeppen H; Hart J; Rubin CM; Thistlethwaite JR
    Transplantation; 1996 Aug; 62(3):370-5. PubMed ID: 8779685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients.
    Younes BS; McDiarmid SV; Martin MG; Vargas JH; Goss JA; Busuttil RW; Ament ME
    Transplantation; 2000 Jul; 70(1):94-9. PubMed ID: 10919581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy.
    Cacciarelli TV; Green M; Jaffe R; Mazariegos GV; Jain A; Fung JJ; Reyes J
    Transplantation; 1998 Oct; 66(8):1047-52. PubMed ID: 9808490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Posttransplant Lymphoproliferative Disease Following Pancreas Transplantation: A 40 Year Single-Center Experience.
    Matar AJ; Finger EB; Maakaron J; Minja E; Ramanathan K; Humphreville V; Rao JS; Fisher J; Sutherland DER; Matas AJ; Kandaswamy R
    Clin Transplant; 2024 Aug; 38(8):e15386. PubMed ID: 39087488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Clinical Features and Outcome of Pediatric Posttransplant Lymphoproliferative Disorder in Recipients of Small Bowel Allograft Versus Isolated Liver Transplantation.
    Chiou FK; Beath SV; Morland B; Hartley J; van Mourik I; Abdel-Hady M; Kelly DA; Sharif K; Gupte GL
    Transplantation; 2020 Jul; 104(7):1429-1436. PubMed ID: 31651718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.
    Wasson S; Zafar MN; Best J; Reddy HK
    J Cardiovasc Pharmacol Ther; 2006 Mar; 11(1):77-83. PubMed ID: 16703222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-transplant lymphoproliferative disorder after liver transplantation: Incidence, long-term survival and impact of serum tacrolimus level.
    Eshraghian A; Imanieh MH; Dehghani SM; Nikeghbalian S; Shamsaeefar A; Barshans F; Kazemi K; Geramizadeh B; Malek-Hosseini SA
    World J Gastroenterol; 2017 Feb; 23(7):1224-1232. PubMed ID: 28275302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Posttransplant lymphoproliferative disorders and gastrointestinal manifestations of Epstein-Barr virus infection in children following liver transplantation.
    Cao S; Cox K; Esquivel CO; Berquist W; Concepcion W; Ojogho O; Monge H; Krams S; Martinez O; So S
    Transplantation; 1998 Oct; 66(7):851-6. PubMed ID: 9798693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphoproliferative disorders after adult kidney transplant: epidemiology and comparison of registry report with claims-based diagnoses.
    Kasiske BL; Kukla A; Thomas D; Wood Ives J; Snyder JJ; Qiu Y; Peng Y; Dharnidharka VR; Israni AK
    Am J Kidney Dis; 2011 Dec; 58(6):971-80. PubMed ID: 21930332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression.
    Shapiro R; Nalesnik M; McCauley J; Fedorek S; Jordan ML; Scantlebury VP; Jain A; Vivas C; Ellis D; Lombardozzi-Lane S; Randhawa P; Johnston J; Hakala TR; Simmons RL; Fung JJ; Starzl TE
    Transplantation; 1999 Dec; 68(12):1851-4. PubMed ID: 10628763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Posttransplant Lymphoproliferative Disorders in Irish Renal Transplant Recipients: Insights From a National Observational Study.
    OʼRegan JA; Prendeville S; McCaughan JA; Traynor C; OʼBrien FJ; Ward FL; OʼDonovan D; Kennedy C; Berzan E; Kinsella S; Williams Y; OʼKelly P; Deady S; Comber H; Leader M; Conlon PJ
    Transplantation; 2017 Mar; 101(3):657-663. PubMed ID: 27214265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence, Risk Factors, Clinical Management, and Outcomes of Posttransplant Lymphoproliferative Disorder in Kidney Transplant Recipients.
    Liu M; Husain S; Famure O; Li Y; Kim SJ
    Prog Transplant; 2019 Jun; 29(2):185-193. PubMed ID: 30845885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients.
    Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV
    Nephrol Dial Transplant; 2012 Jul; 27(7):2971-9. PubMed ID: 22273720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-transplant lymphoproliferative disorders in liver transplant recipients: a clinicopathological study.
    Lo RC; Chan SC; Chan KL; Chiang AK; Lo CM; Ng IO
    J Clin Pathol; 2013 May; 66(5):392-8. PubMed ID: 23423516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary sclerosing cholangitis and other risk factors for post-transplant lymphoproliferative disease after liver transplantation in adults.
    Ruijter BN; Tushuizen ME; van der Helm D; Hew M; Reeven M; Vossen ACTM; Metselaar HJ; Alwayn IPJ; Dubbeld J; Polak WG; van Hoek B
    Liver Transpl; 2024 Jun; 30(6):640-646. PubMed ID: 37698933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.